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Agouti-relatedprotein(AgRP)isa4-kDacystine-knotpeptideofhumanoriginwithfourdisulﬁdebondsandfoursolvent-exposed
loops. The cell adhesion receptor integrin αvβ3 is an important tumor angiogenesis factor that determines the invasiveness and
metastatic ability of many malignant tumors. AgRP mutants have been engineered to bind to integrin αvβ3 with high aﬃnity






   
-tetraacetic acid (DOTA) and radiolabeled with 111In. The stability of the radiopeptides 111In-DOTA-AgRP-7C
and 111In-DOTA-AgRP-6E was tested in phosphate-buﬀered saline (PBS) and mouse serum, respectively. Cell uptake assays
of the radiolabeled peptides were performed in U87MG cell lines. Biodistribution studies were performed to evaluate the in
vivo performance of the two resulting probes using mice bearing integrin-expressing U87MG xenograft tumors. Both AgRP
peptides were easily labeled with 111In in high yield and radiochemical purity (>99%). The two probes exhibited high stability
in phosphate-buﬀered saline and mouse serum. Compared with 111In-DOTA-AgRP-6E, 111In-DOTA-AgRP-7C showed increased
U87MG tumor uptake and longer tumor retention (5.74±1.60 and 1.29±0.02%ID/g at 0.5 and 24h, resp.), which was consistent
with measurements of cell uptake. Moreover, the tumor uptake of 111In-DOTA-AgRP-7C was speciﬁcally inhibited by coinjection
with an excess of the integrin-binding peptidomimetic c(RGDyK). Thus, 111In-DOTA-AgRP-7C is a promising probe for targeting
integrin αvβ3 positive tumors in living subjects.
1.Introduction
Molecular imaging is a rapidly evolving ﬁeld in biomedical
r e s e a r c ha n dp r o v i d e sp o w e r f u lt e c h n i q u e st on o n i n v a s i v e l y
study a variety of important characteristics of cancers, such
as tumor metabolism, proliferation, hypoxia, and receptor
expression[1–3].Therefore,novelmolecularprobesthattar-
get these characteristics have been under active and intensive
development and investigation. Many platforms including
small molecules, peptides, proteins, and nanoparticles have
been explored in order to develop molecular probes to image
a variety of important disease biomarkers [4, 5].
Cystine-knot peptides consist of a stable core motif
of at least three disulﬁde bonds that are interwoven into
a “knot” conformation. There is great sequence diversity
among cystine-knot family members, as only the disulﬁde-
bonded core is conserved; consequently, the loops connect-
ing the cysteine residues are highly tolerant to substitution
or incorporation of additional amino acid residues [6–
8]. Previously, we used a truncated form of the Agouti-
related protein (AgRP∗), a 4-kDa cystine-knot peptide with
four disulﬁde bonds and four solvent-exposed loops, as a
molecular scaﬀold for directed evolution. In this study, high-
throughput methods were used to screen a yeast-displayed2 Journal of Biomedicine and Biotechnology
Table 1: Amino acid sequences of the AgRP∗ mutants 7C and 6E
used in this study. DOTA was site-speciﬁc conjugated to the N-




Red lines represent the disulﬁde bonds between Cys1–Cys4,C y s 2–Cys5,
Cys3–Cys8,a n dC y s 6–Cys7 in the AgRP∗-based cystine-knot peptides.
AgRP∗ library to identify several mutants with high aﬃnity
and speciﬁcity for αvβ3 integrin [8].
The cell adhesion receptor integrin αvβ3 is an important
tumor angiogenesis factor that determines the invasiveness
and metastatic ability of many malignant tumors. It is upreg-
ulated on the tumor cell surface and also overexpressed on
activated endothelial cells around the tumor tissues [9–11].
Many radiolabeled probes have been developed for imaging
integrin expression using positron emission tomography
(PET) or single-photon emission computed tomography
(SPECT) [12–15]. In our recent research, the 64Cu-DOTA
conjugated AgRP∗ mutant 7C (64Cu-DOTA-AgRP-7C) was
successfully developed for PET imaging of integrin αvβ3
positive tumors. This study demonstrated the potential of
AgRP∗-based integrin-binding peptides for use as in vivo
molecular imaging applications and highlighted cystine-
knots as promising molecules for further development as
diagnostics or therapeutics against diﬀerent tumor targets
[13].
In the current study, to further characterize the in vivo
performance of integrin-binding AgRP∗-based peptides and
also evaluate their potential use for SPECT imaging appli-
cations, two DOTA-conjugated AgRP∗ mutants (DOTA-
AgRP-7C and DOTA-AgRP-6E; Table 1) were synthesized
and radiolabeled with the gamma emitter 111In (t1/2 = 2.8
days). Tumor uptake, biodistribution, and stability of the
resulting probes were evaluated in integrin αvβ3 positive
human glioblastoma U87MG tumor xenograft models.
2.MaterialsandMethods
2.1. Chemicals, Reagents, and Instruments. DOTA-AgRP-
7C and DOTA-AgRP-6E were synthesized and reported
previously [13]. 111InCl3 was purchased from PerkinElmer.
All other reagents were obtained from Fisher Scientiﬁc
Co. unless otherwise speciﬁed. Female athymic nude mice
(nu/nu, 5-6 weeks old) were purchased from Charles River
Laboratory (Wilmington, MA, USA). A CRC-15R PET dose
calibrator (Capintec Inc., Ramsey, NJ, USA) was used for
all radioactivity measurements. Reversed phase high perfor-
mance liquid chromatography (RP-HPLC) was performed
on a Dionex Summit HPLC system (Dionex Corporation,
Sunnyvale, CA, USA) equipped with a 170U 4-Channel
UV-Vis absorbance detector and radioactivity detector (Car-
roll and Ramsey Associates, model 105S, Berkeley, CA).
UVdetectionwavelengthswere218nm,254nm,and280nm
for all the experiments. Both semipreparative (Vydac, Hes-
peria, CA. 218TP510-C18, 10mm × 250mm) and analytical
RP-HPLC columns were used. The mobile phase was solvent
A, 0.1% triﬂuoroacetic acid (TFA)/H2O, and solvent B,
0.1%TFA/acetonitrile.
2.2. Cell Line and Cell Culture. The human glioblastoma
cell line U87MG was obtained from American Type Culture
Collection (ATCC; Manassas, VA, USA). The cells were
maintained as monolayer cultures in Dulbecco’s Modiﬁed
Eagle Medium (DMEM) containing high glucose (GIBCO,
Carlsbad,CA,USA),whichwassupplementedwith10%fetal
bovineserum(FBS;GIBCO)and1%penicillin-streptomycin
(GIBCO). The cells were expanded in tissue culture dishes
andkeptinahumidiﬁedatmosphereof5%CO2 at37◦C.The
media was changed every other day. A conﬂuent monolayer
was detached with 0.5% Trypsin-EDTA, 0.01M PBS (pH
7.4), and dissociated into a single-cell suspension for further
cell culture and binding experiments.
2.3. Peptide Radiolabeling. DOTA-AgRP-7C or DOTA-
AgRP-6E were radiolabeled with 111In by incubating 15μg
of peptide in 37MBq (1mCi) 111InCl3 and 100μLo f
0.1N NH4OAc (pH 5.0–5.5) buﬀer, at 80◦C for 45min.
Theradiolabeledconjugates, 111In-DOTA-AgRP-7Cor 111In-
DOTA-AgRP-6E, were puriﬁed using a PD-10 column (GE
Healthcare Life Sciences, Piscataway, NJ, USA) and eluted
with PBS.
2.4. In Vitro Stability Assays. Radiolabeled AgRP∗ peptides
were incubated in 0.01M PBS (pH 7.4) at 37◦Cf o r2 4ha n d
monitoredfordegradationbyHPLC.Stabilitywasalsotested
by incubating 0.74 MBq (20μCi) 111In-DOTA-AgRP-7C or
111In-DOTA-AgRP-6E in 400μL of mouse serum at 37◦C
for 2h. Afterward, the mixture was re-suspended in 0.5mL
of DMF containing 5μLo fT r i t o nX - 1 0 0a n dc e n t r i f u g e d
at 16,000g for 2min. The supernatant, which contained
>95% of the starting radioactivity, was ﬁltered using a
10K NanoSep device (Pall Corporation, East Hills, NY,
USA). Greater than 99% of the radioactive material passed
through this ﬁlter. The samples were analyzed by radio-
HPLC, and the percentage of intact peptide was determined
by quantifying peaks corresponding tothe intactpeptide and
to the degradation products.
2.5. In Vitro Cell Uptake Assay. Cell uptake studies were
performed as previously described [16]. Brieﬂy, U87MG
cells were seeded at a density of 0.2 × 106 in 12-
well tissue culture plates and allowed to attach overnight.
After washing three times with serum-free DMEM, cells
were incubated with 111In-DOTA-AgRP-7C or 111In-DOTA-
AgRP-6E (0.5μCi/well) with or without the integrin-binding
peptidomimetic, c(RGDyK), (2μg/well) at 37 or 4◦Cf o r
15, 60, and 120min, respectively. Cells were washed three
times with chilled PBS containing 0.2% BSA and dissolvedJournal of Biomedicine and Biotechnology 3
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Figure 1: Stability analysis of 111In-DOTA-AgRP-7C (a) and (b), and 111In-DOTA-AgRP-6E (c) and (d) in PBS and mouse serum. The two
radiopeptides were incubated with PBS for 24h at room temperature, and mouse serum for 2h at 37◦C.
by treatment with 0.1N NaOH at room temperature for
5min. The cells’ suspensions were collected and the resultant
radioactivity was measured using a γ-counter (PerkinElmer
1470, Waltham, MA, USA). Cell uptake was expressed as
the percentage of added radioactivity. Experiments were
performed twice with triplicate wells.
2.6. Biodistribution Studies. All animal studies were carried
out in compliance with federal and local institutional rules
for animal experimentation. Approximately, 107 U87MG
cells were suspended in PBS and subcutaneously implanted
in the left shoulders of female athymic nu/nu mice. Tumors
were allowed to grow to a size of 0.5cm (2-3 weeks) before
imaging experiments were performed. For biodistribution
studies, U87MG tumor-bearing mice (n = 3f o re a c hg r o u p )
were injected with 111In-DOTA-AgRP-7C (0.259–0.37MBq,
7–10 Ci) or 111In-DOTA-AgRP-6E (0.296–0.444MBq, 8–
12μCi) via the tail vein and sacriﬁced at diﬀerent time points
(0.5, 2, 24, and 48h) after injection (p.i.). Tumor and normal
tissues of interest were removed and weighed, and their
radioactivity was measured with a γ-counter. Radioactivity
uptake was expressed as the percent injected dose per gram
of tissue (%ID/g). To test the in vivo αvβ3 integrin targeting
speciﬁcity of the probe, U87MG tumor-bearing mice (n = 3
for each group) were injected via the tail vein with a mixture
of 111In-DOTA-AgRP-7C (0.259–0.37MBq, 7–10μCi) and
330μgo fc ( R G D y K ) .T h em i c ew e r es a c r i ﬁ c e da t2hp . i .a n d
thebiodistributionoftheradiolabeledpeptidewasmeasured
as above.
2.7. Statistical Analysis. Quantitative data were expressed as
mean ± SD. Means were compared using the Student t-
test. A 95% conﬁdence level was chosen to determine the
signiﬁcance between groups, with P values of less than 0.05
indicating signiﬁcant diﬀerences.
3. Results
3.1. Radiolabeling. Due to the high thermal stability of
cystine-knot peptides, DOTA-AgRP-6E and DOTA-AgRP-
7C were easily labeled with 111InCl3 by incubation in
NH4OAc buﬀer (pH 5.0–5.5) at 80◦C for 45min. Radi-
olabeled peptides were puriﬁed by PD-10 columns. The
radiochemical yield for both peptides was determined by
radio-HPLC to be ∼50% and the radiochemical purity as
also determined by radio-HPLC was greater than 99%.
The speciﬁc activity of the peptides was determined to be
approximately 0.25mCi/nmol.
3.2. Peptide Stability. Both 111In-DOTA-AgRP-7C and 111In-
DOTA-AgRP-6E were radiochemically stable after 24h in
0.01MPBS (pH 7.4), as determined by radio-HPLC analysis
(Figures 1(a) and 1(c)). Furthermore, radio-HPLC analysis
revealed that over 95% of the probes remained intact after
2h incubation with mouse serum at 37◦C (Figures 1(b) and
1(d)).
3.3. In Vitro Cell Uptake. T h eu p t a k eo f111In-DOTA-AgRP-


































































Figure 2: In vitro cell uptake assay of 111In-DOTA-AgRP-7C (a) and 111In-DOTA-AgRP-6E (b) on U87MG cells at 37◦C and 4◦C with or
without c(RGDyK) blocking peptide (n = 3, mean ± SD).
cells and the results are shown in Figure 2. During the
ﬁrst 15min incubation period at 37◦C, 111In-DOTA-AgRP-
7C exhibited rapid cell accumulation, followed by a steady
increase in binding and receptor-mediated uptake through-
out the experiment. The cell uptake values of 111In-DOTA-
AgRP-7C after 15, 60 and 120min at 37◦Cw e r e1 .70 ±
0.07%, 2.46 ± 0.29%, and 2.76 ± 0.25%, and at 4◦Cw e r e
1.05 ± 0.21%, 1.19 ± 0.27%, and 1.26 ± 0.38%, respectively
(Figure 2(a)). Thus, a ∼2 fold greater accumulation of probe
was observed in cells incubated at 37◦C compared to those
incubated at 4◦C, which is indicative of internalization that
occurs at physiological temperature. Moreover, cell surface
binding and internalization were signiﬁcantly inhibited by
the addition of a large molar excess of the integrin-binding
peptidomimetic c(RGDyK) (P<0.05) (Figure 2(a)). After
1h, cell uptake of the probe was inhibited 90% and 86%
at 37◦Ca n d4 ◦C, respectively, demonstrating that the probe
speciﬁcally targets cell surface integrin receptors.
In comparison, the U87MG cell uptake values of 111In-
DOTA-AgRP-6E after 15, 60, and 120min at 37◦Cw e r e
0.32 ± 0.01%, 0.85 ± 0.28% and 0.96 ± 0.07%, and at
4◦Cw e r e0 .22 ± 0.04%, 0.45 ± 0.04%, and 0.50 ± 0.05%,
respectively (Figure 2(b)). Similar to 111In-DOTA-AgRP-7C,
a ∼2-fold increase in uptake of 111In-DOTA-AgRP-6E was
found at 37◦Cc o m p a r e dt o4 ◦C. Probe accumulation was
blocked by the addition of c(RGDyK), with reductions in cell
uptakeof38%at37◦Cand42%at4◦Cafter1h(Figure 2(b)).
3.4. Biodistribution Studies. The biodistribution of 111In-
DOTA-AgRP-7C was examined in nude mice bearing
U87MG human glioblastoma tumors. The results of these
experiments are shown in Table 2. Tumor uptake of the
probe was 5.74 ± 1.60, 2.35 ± 0.36, 1.29 ± 0.02, and 0.76 ±
0.17%ID/g at 0.5, 2, 24, and 48h, respectively, indicating
relatively high tumor uptake and moderate tumor retention.
The probe was found to have rapid blood clearance, with
radioactivity levels of 0.68 ± 0.26 and 0.10 ± 0.02%ID/g
remaining in the blood after 0.5 and 2h p.i., respectively.
Moreover, whole-body clearance of radioactivity was equally
rapid. Except for the kidneys, accumulation in most organs
examined were all lower than 1%ID/g at 2h p.i. Prominent
uptake was observed in the kidneys at early time points
(33.93 ± 8.35%ID/g at 0.5h), with decreasing accumulation
from2to48hp.i.Thesedataclearlyindicatearenalexcretion
route and metabolic processing of the probe by the kidneys.
With the rapid clearance of the radiotracer from blood
and other normal organs, 111In-DOTA-AgRP-7C exhibited
high tumor-to-normal organ ratios in the blood, muscle,
lung, liver, spleen, and pancreas (Table 2 and Figure 3(b)).
For example, at 2h p.i., the tumor-to-blood and tumor-to-
muscle ratio of 111In-DOTA-AgRP-7C was 25.8 and 39.8,
respectively. To conﬁrm in vivo integrin binding speciﬁcity,
co-injection of 111In-DOTA-AgRP-7C with a large molar
excess of c(RGDyK) signiﬁcantly reduced tumor uptake by
∼77% (0.54 ± 0.07 versus 2.35 ± 0.36%ID/g at 2h p.i., P<
0.05) (Table 2). Signiﬁcant diﬀerences were also found for
probe uptake in normal tissues such as spleen upon addition
of c(RGDyK) blocking peptide.
The biodistribution results of 111In-DOTA-AgRP-6E are
summarized in Table 3. Intermediate tumor uptake of 111In-
D O T A - A g R P - 6 Ew a so b s e r v e da t0 . 5 ,2 ,a n d2 4hp . i . ,w i t h
values of 1.76 ± 0.34, 1.21 ± 0.21, and 0.89 ± 0.06%ID/g,
respectively. The probe also showed rapid blood clearance,
with radioactivity levels of 1.27±0.53 and 0.06±0.05%ID/g
remaining in the blood after 0.5 and 2h. In addition, low
normal tissue accumulation was seen with the exception of
thekidneys(15.37±3.19%ID/gand14.68±1.98%ID/gat0.5
and 2h, resp.). Finally, because of the rapid clearance of the
probe from the blood and other organs, 111In-DOTA-AgRP-
6Ealsodisplayed hightumor-to-blood andtumor-to-muscle
ratios at 2 and 24h p.i. (Table 3).
4. Discussion
The native AgRP is a neuropeptide produced in the human
brain that plays an important biological role in increasing
appetite and decreasing metabolism and energy expenditure
[17–19]. The C-terminus of AgRP is a cystine-knot peptide
which contains a biologically active loop that naturally binds
to melanocortin receptors. A truncated form of the AgRPJournal of Biomedicine and Biotechnology 5
Table 2: Biodistribution results for 111In-DOTA-AgRP-7C in nude mice bearing subcutaneous U87MG human glioblastoma xenografts.
Data are expressed as the percent injected dose per gram of tissue (%ID/g) after intravenous injection of the probe (0.259–0.37MBq, 7–
10μCi) at 0.5, 2, 24, and 48h (n = 3). For 2h blocking group, mice were coinjected with 330μg of c(RGDyK).
Tissues 0.5h 2h 24h 48h 2h Blocking
%ID/g
Tumor 5.74 ±1.60 2.35 ±0.36 1.29 ±0.02 0.76 ±0.17 0.54 ± 0.07
∗
Brain 0.04 ±0.02 0.02 ±0.01 0.01 ±0.00 0.01 ±0.01 0.01 ±0.00
Blood 0.68 ±0.26 0.10 ±0.02 0.01 ±0.00 0.01 ±0.00 0.07 ±0.01
Heart 0.45 ±0.16 0.12 ±0.02 0.04 ±0.01 0.03 ±0.00 0.06 ±0.01
Lung 2.11 ±0.65 0.86 ±0.20 0.26 ±0.09 0.12 ±0.02 0.41 ±0.08
Liver 0.80 ±0.19 0.43 ±0.16 0.24 ±0.03 0.19 ±0.03 0.20 ±0.04
Spleen 1.70 ±0.62 0.88 ±0.21 0.58 ±0.09 0.46 ±0.10 0.21 ± 0.03
∗
Kidneys 33.93 ±8.35 30.59 ±4.62 19.12 ±2.17 8.47 ±0.04 34.52 ±4.02
Muscle 0.30 ±0.13 0.06 ±0.01 0.04 ±0.01 0.02 ±0.01 0.10 ±0.10
Pancreas 0.42 ±0.17 0.13 ±0.03 0.09 ±0.01 0.05 ±0.01 0.13 ±0.03
Bone 1.41 ±0.36 0.63 ±0.05 0.39 ±0.07 0.24 ±0.05 0.45 ±0.01
Stomach 2.17 ±0.49 0.80 ±0.06 0.21 ±0.01 0.14 ±0.02 0.24 ± 0.04
∗
Intestine 2.02 ±0.71 0.60 ±0.13 0.29 ±0.02 0.22 ±0.03 0.25 ± 0.06
∗
Ratio
Tumor-to-blood 8.90 ±3.09 25.81 ±10.46 127.53±30.50 144.12±36.33 8.18 ± 0.15
∗
Tumor-to-muscle 20.56 ±6.40 39.83 ±9.16 37.69 ±9.81 41.12 ±8.62 14.03±13.45
∗
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Figure 3: U87MG tumor uptake for 111In-DOTA-AgRP-7C and 111In-DOTA-AgRP-6E at 0.5, 2, and 24h p.i. (a). Tumor (T)-to-normal
organ ratios for 111In-DOTA-AgRP-7C with or without c(RGDyK) blocking peptide at 2h after the injection of the probe (b).
cystineknotpeptide,AgRP∗ isemergingasahighlyattractive
platform for developing novel molecular imaging probes
[20, 21]. AgRP∗ is small in size (∼4kDa) and possesses a
rigidstructure,yetcontainsfoursolvent-accessibleloopsthat
could be used for mutagenesis [8]. In addition, peptides
based on AgRP∗ are likely to be nonimmunogenic due
to their human origin and high thermal and proteolytic
stability; Furthermore, AgRP∗ is amenable to recombinant
and synthetic production, which will allow site-speciﬁc in-
corporation of labels or chemical functionality in future
studies.
In our previous studies, the AgRP∗-based αvβ3 inte-
grin binder AgRP-7C was discovered and used for PET
imaging of tumor angiogenesis [8, 13]. Excellent in vivo
tumor imaging contrast was achieved which demonstrates
the success of using AgRP∗-based scaﬀolds for molecular
probe development [13]. This study motivated us to fur-
ther evaluate engineered AgRP∗-based integrin targeting
peptides for potential SPECT imaging applications. The
high aﬃnity binder DOTA-AgRP-7C (IC50 ∼20nM) and
moderate aﬃnity binder DOTA-AgRP-6E (IC50 ∼130nM)
were radiolabeled with 111In and tested for their ability to
target tumors in living subjects.
The cystine-knot motif of AgRP∗ conferred high stability
to the radiolabeled peptides. Compared to the reaction
temperature (37◦C) used for 64Cu radiolabeling of AgRP-7C,6 Journal of Biomedicine and Biotechnology
Table 3: Biodistribution results for 111In-DOTA-AgRP-6E in nude mice bearing subcutaneous U87MG human glioblastoma xenografts.
Data are expressed as the percent %ID/g after intravenous injection of the probe (0.296–0.444MBq, 8–12μC i )a t0 . 5 ,2 ,a n d2 4h( n = 3).
Tissue 0.5h 2h 24h
%ID/g
Tumor 1.76 ±0.34 1.21 ±0.21 0.89 ±0.06
Brain 0.06 ±0.01 0.02 ±0.01 0.02 ±0.01
Blood 1.27 ±0.53 0.06 ±0.05 0.01 ±0.00
Heart 0.80 ±0.24 0.18 ±0.06 0.12 ±0.02
Lung 1.86 ±0.56 0.54 ±0.12 0.27 ±0.02
Liver 0.87 ±0.20 0.52 ±0.01 0.48 ±0.02
Spleen 1.36 ±0.26 0.83 ±0.05 0.65 ±0.06
Kidneys 15.37 ±3.19 14.68 ±1.98 6.87 ±1.19
Muscle 0.64 ±0.09 0.15 ±0.07 0.07 ±0.01
Pancreas 0.57 ±0.23 0.20 ±0.06 0.14 ±0.01
Bone 1.18 ±0.15 0.56 ±0.10 0.36 ±0.04
Stomach 2.02 ±0.47 0.87 ±0.14 0.53 ±0.02
Intestine 2.04 ±0.54 1.13 ±0.14 0.93 ±0.04
Ratio
Tumor-to-blood 1.71 ±1.21 33.04 ±23.28 142.32 ± 3.39
Tumor-to-muscle 2.75 ±0.28 9.20 ±3.88 13.07 ±1.94
Data are presented as mean ± SD (n = 3).
111In radiolabeling of DOTA-AgRP-7C and DOTA-AgRP-
6E was performed at 80◦C. The high reaction temperature
did not appear to denature the peptides as demonstrated
by the cell uptake and biodistribution studies. Similar
to 64Cu-DOTA-AgRP-7C, both 111In-DOTA-AgRP-7C and
111In-DOTA-AgRP-6E were found to be stable in PBS buﬀer
for at least 24h and in mouse serum for 2h.
In biodistribution studies, 111In-DOTA-AgRP-7C shows
rapid tumor targeting and uptake in integrin αvβ3 expressing
human glioblastoma xenografts (5.74 ± 1.60%ID/g at 0.5h),
which is signiﬁcant higher than that of 64Cu-DOTA-AgRP-
7C (1.92 ± 0.48%ID/g at 0.5h, P<0.05). Moreover,
111In-DOTA-AgRP-7C shows fast blood clearance (0.68 ±
0.26%ID/g at 0.5h), through the kidney-urinary system. The
kidneyuptakeof 111In-DOTA-AgRP-7Cis30.59±4.62%ID/g
at 2h p.i., which is much lower than that of 64Cu-DOTA-
AgRP-7C (60.22±17.52%ID/g at 2h). Lastly, the uptake and
retention of 111In-DOTA-AgRP-7C in other normal organs
is low (Table 2). Overall, these data indicate that using a
diﬀerent radiometal (111In compared to 64Cu) preserves the
tumor targeting ability of engineered cystine-knot peptides,
but signiﬁcantly improves the in vivo performance of the
resulting probe.
Both 111In and 64Cu labeled DOTA-AgRP-7C exhibit
high renal uptake, which is likely attributed to (1) the long
residence time of radiometabolites produced by lysosomal
degradation of the radiolabeled peptides within renal cells;
(2) the overall positive charge of the peptides [22–25].
Several strategies previously reported that the accumulation
of radiopeptide in the kidneys can be eﬀectively reduced by
coinjection of cationic amino acid such as lysine, or poly-
lysine molecules [16, 26]. These methods could potentially
be explored to reduce the radiation dose to kidney.
Biodistribution studies reveal that 111In-DOTA-AgRP-
7C has signiﬁcant higher tumor uptake than that of 111In-
DOTA-AgRP-6E at diﬀerent time points (0.5, 2, and 24h)
(Figure 3(a)). This could be related to the stronger integrin
binding aﬃnity of AgRP-DOTA-7C compared to AgRP-
DOTA-6E (IC50:2 2 .6 ± 3.9nM versus 125.5 ± 16.6nM,
resp.) [27]. Both probes display good retention in tumor
a n dl o wu p t a k e si nm o s to fn o r m a lo r g a n s( T a b l e s2 and 3).
Interestingly,thekidneyuptakeof 111In-DOTA-AgRP-6Ewas
signiﬁcantly lower than that of 111In-DOTA-AgRP-7C (14.68
versus 30.59%ID/g at 2h p.i.), suggesting that modiﬁcation
of the amino acid sequence of the engineered loop of AgRP∗
may help to optimize in vivo behavior. Because 111In-DOTA-
AgRP-7C showed higher tumor uptake compared to 111In-
DOTA-AgRP-6E, the in vivo integrin targeting speciﬁcity of
the probe was further conﬁrmed by a blocking study, using a
peptidomimetic (c(RGDyK)) that binds to the same epitope
on integrin receptors. Compared to the nonblocking group,
the tumor uptake of 111In-DOTA-AgRP-7C is signiﬁcantly
decreaseduponco-injectionofc(RGDyK)(2.35±0.36versus
0.54 ± 0.07%ID/g at 2h, resp.) Table 2 and Figure 3(b),i n
agreement with the in vitro cell uptake results.
In a previous study, the tumor uptake of 111In-DOTA-
c(RGDfK) was reported as 6.28%ID/g at 1h p.i. in a SKOV3
xenograft model [28]. In comparison, we show that the
tumor uptake of 111In-DOTA-AgRP-7C is 5.74%ID/g at
0.5h p.i. in a U87MG xenograft model. Importantly, 111In-
DOTA-AgRP-7C and 111In-DOTA-AgRP-6E were found to
have much lower uptake and faster clearance in liver,
lung, spleen and other normal tissues compared to 111In-
DOTA-c(RGDfK). The fast clearance of 111In-labeled AgRP∗
mutants resulted in high tumor-to-blood and tumor-
to-muscle ratios at 24 and 48h p.i. (Tables 2 and 3,Journal of Biomedicine and Biotechnology 7
Figure 3), demonstrating the advantages of using an AgRP∗-
based scaﬀold for imaging probe development [28, 29].
5. Conclusions
In summary, we tested the αvβ3 integrin-targeted cystine-
knot peptides 111In-DOTA-AgRP-6E and 111In-DOTA-
AgRP-7C as SPECT imaging agents in mouse tumor models.
Compared to 111In-DOTA-AgRP-6E, 111In-DOTA-AgRP-7C
exhibits higher integrin binding aﬃnity and tumor uptake.
Moreover, this probe demonstrates rapid tumor uptake, high
tumor-to-normal tissue contrast, and favorable pharmacoki-
netics. These results suggest that AgRP∗ mutant 7C has
potential for clinical translation as a new SPECT imag-
ing agent for integrin αvβ3 positive tumors. Furthermore,
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